Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.
Source: https://www.cnbc.com/2024/03/08/novo-no ... -drug.html
Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug
